This narrative review examines treatments for neovascular glaucoma, a condition where new blood vessels grow in the eye due to retinal ischemia. The study looks at how intravitreal anti-VEGF injections, panretinal photocoagulation, antiangiogenic bridging, and ischemia-directed therapies work together. It notes that these treatments can cause the abnormal blood vessels to regress rapidly. The review does not report specific numbers or safety data because it summarizes existing information rather than testing new data.
The main point is that long-term success requires integrated, individualized care. This means doctors must couple antiangiogenic bridging with durable management of retinal ischemia and optimized surgical strategies. Simply using one treatment is not enough for lasting results. The review highlights that the condition starts with retinal ischemia, which elevates VEGF and other mediators that induce rubeosis iridis and fibrovascular membrane formation at the angle.
Readers should understand that this is a review of existing literature, not a new clinical trial. The evidence comes from summarizing what is already known about these therapies. While the findings suggest a link between integrated care and better outcomes, the review does not provide new proof or specific numbers. Patients should discuss these options with their eye care team to find the right plan for their specific situation.